Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 5, 2007, Pages 481-486

  Dudek, Arkadiusz Z ^a,c   Larson, Timothy ^b   Keshtgarpour, Mani ^a   Kumar, Priya ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b North Memorial Humphrey Cancer Center   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Biweekly; Carboplatin; Gemcitabine; Phase I; Solid tumors

Indexed keywords

ANTIDIARRHEAL AGENT; CARBOPLATIN; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG SAFETY; DYSPNEA; ERYTHROCYTE TRANSFUSION; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HOSPITALIZATION; HUMAN; KIDNEY CARCINOMA; LOWER GASTROINTESTINAL BLEEDING; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CARCINOMA; PATIENT COMPLIANCE; PENIS CARCINOMA; RESPIRATORY FAILURE; SEPSIS; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TASTE; THERAPY DELAY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PATIENT SELECTION;

EID: 35148837635     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31804b45c3     Document Type: Article

References (24)

1. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005;47:69-80.
2. Crino L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol. 1999;17:3522-3530.
3. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
4. Kunikane H, Kurita Y, Watanabe K, et al. A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule. Int J Clin Oncol. 2001;6:284 -290.
5. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380-8388.
6. Iaffaioli RV, Tortoriello A, Facchini G, et al. Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer. J Clin Oncol. 1999;17:921-926.
7. Gajra A, Mehdi SA, Kirshner J, et al. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma. Lung Cancer. 2001;32:189-196.
8. Tassinari D, Drudi G, Panzini I, et al. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial. Int J Clin Oncol. 2001;6:279-283.
9. Pollera CF, Ceribelli A, Creccon M, et al. Weekly gemcitabine in advanced or metastatic solid tumors. Invest New Drugs. 1994;12:111-119.
10. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23:8380-8388.
11. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung carcinoma. Cancer. 2003;98:542-553.
12. Colomer R, Llombart-Cussac A, Lluch A, et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol. 2004;15:201-206.
13. Isla D, Rosell R, Sanchez JJ, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2001;19:1071-1077.
14. Stathopoulos GP, Rigatos SK, Pergantas N, et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol. 2002;20:37-41.
15. Soo RA, Wang LZ, Tham LS, et al. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol. 2006;17:1128-1133.
16. Ichiki M, Gohara R, Fujiki R, et al. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2003;52:67-72.
17. Ng EW, Sandler AB, Robinson L, et al. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group Study. Am J Clin Oncol. 1999;22:550-553.
18. Obasaju CK, Ye Z, Bloss LP, et al. Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules. Clin Lung Cancer. 2005;7:202-207.
19. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004;64:479-484.
20. Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma: a Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 2006;106:297-303.
21. Nogue-Aliguer M, Carles J, Arrivi A, et al. Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy. Cancer. 2003;97:2180-2186.
22. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer. 2003;97:2791-2797.
23. Nasr FL, Chahine GY, Kattan JG, et al. Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer. 2004;5:117-122; discussion 123-124.
24. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study. Gynecol Oncol. 2004;92:152-159.